DelveInsight Blog
Map the latest in Pharmaceutical, Healthcare, Medical Devices and Biotech Space with DelveInsight’s panoramic market analysis while the Pharma Industry continues to rapidly evolve with several approvals,failures, acquisitions, and partnerships teeing up the domain.
iVEAcare’s $27.5 Million Series A Funding; AI Medical Service Joint Research Agreement with Mahidol University; CERENOVUS Launched Catheter; Cochlear FDA Clearance for The Osia System; Immunovia Announced Positive Results From The Model-Development Study; Hyalex Orthopaedics First Patients Treatment
iVEAcare Launched $27.5 Million Series A Funding from Leading Medtech Investors On April 24, 2024, iVEAcare, announced the closure of a $27.5 million Series A financing. The financing was led by Vensana Capital, which was joined by Treo Ventures, Hatteras Venture Partners, and an undisclosed strategic partner. iVEAcare is the third spin-off from NuXcel, a medical device accelerator and backed by Treo Ventures. Alongside securing funding, the company revealed Todd Kerkow's new role as President and CEO. Kerkow brings extensive expertise in the medical device sector, boasting almost thirty years…
Ravulizumab Outshines Competitors: Insights from NMOSD Treatment Analysis
ULTOMIRIS (ravulizumab-cwvz) is the first and only long-acting C5 complement inhibitor that offers patients with aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) the potential to live relapse-free. In comparison to other therapeutic options, ravulizumab stands out as a symbol of pioneering progress and efficacy, surpassing competitors with its remarkable reduction in relapse risk and promising outcomes for patients with NMOSD. In the tapestry of autoimmune diseases, NMOSD emerges as a formidable adversary, wreaking havoc on the central nervous system (CNS). Amidst the arsenal of approved therapies, the quest…
Riliprubart’s Ascendancy: Phase II Results Illuminate Path Forward for CIDP Treatment
Sanofi is presently engaged in the exploration of Riliprubart (SAR445088), a monoclonal antibody designed to selectively target the serine protease C1s, in pursuit of its potential therapeutic application in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Riliprubart unveils compelling efficacy in CIDP treatment, fostering improvement among Standard-of-Care (SOC)-Treated participants and igniting a resurgence in SOC-Refractory individuals, accompanied by notable enhancements in disability measures and a reduction in plasma neurofilament light chain. In the labyrinth of CIDP, where demyelination and inflammation entwine to ensnare the afflicted, complement activation emerges as a malevolent orchestrator…
-Agonist.png "Toll-like Receptors Agonist")
